Pfizer Trades Below 10x Earnings: Why Does Johnson & Johnson Command More Than Twice the Multiple?
FROM THE WIRE · FINANCE.YAHOO.COM
Pfizer Inc. (NYSE:PFE) looks cheap based on its forward P/E, but its earnings outlook helps explain the discount. But unlike Johnson & Johnson or Eli Lilly, Pfizer's low earnings multiple is not being driven lower by rapid earnings growth. It is expected to rise because earnings…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralA relative valuation analysis of pharma stocks explaining different price multiples based on growth outlooks.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Pfizer trades at 9.34x 2026 earnings with expected EPS decline of 7.61% in 2026.
- 02Johnson & Johnson commands higher multiples due to accelerating growth prospects after 2026.
- 03Pfizer's low multiple reflects earnings decline, not rapid growth like JNJ or Eli Lilly.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Pfizer Inc.28.00 USDMarket closedtoday +1.82%Neutral Johnson & Johnson258.45 USDMarket closedtoday +1.44%Positive Eli Lilly and Company1,188.72 USDMarket closedtoday +2.70%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets